Albert Qin
Fortuna: 3 M $ al 31/05/2026
Fortuna: 3 M $ al 31/05/2026
Albert Qin is currently the Chief Medical Officer at PharmaEssentia Corp.
He previously worked as the Executive Officer & Chief Scientific Officer at SymBio Pharmaceuticals Ltd.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PHARMAESSENTIA CORP. 0,03 % | 28/02/2026 | 98.545 ( 0,03 % ) | 3 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| PHARMAESSENTIA CORPORATION | Director Técnico/Científico/I+D | - |
| Empresas | Cargo | Fin |
|---|---|---|
| SYMBIO PHARMACEUTICALS LIMITED | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
SymBio Pharmaceuticals Ltd.
SymBio Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutics for cancer and other related diseases | Health Technology |
PharmaEssentia Corp.
PharmaEssentia Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells therapeutic products for the treatment of hematologic diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.